Recipient PTPN22 -1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies

J. Luis Espinoza, Akiyoshi Takami, Makoto Onizuka, Yasuo Morishima, Takahiro Fukuda, Yoshihisa Kodera, Hideki Akiyama, Koichi Miyamura, Takehiko Mori, Shinji Nakao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PTPN22 is a critical negative regulator of T cell responses. Its promoter gene variant (rs2488457, -1123G>C) has been reported to be associated with autoimmune diseases. This study analyzed the impact of the . PTPN22 variant on transplantation outcomes in a cohort of 663 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. The recipient C/C genotype versus the recipient G/G genotype resulted in a lower incidence of grade II-IV acute graft-versus-host disease (hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.29-0.85; . P = .01), as well as a higher incidence of relapse (HR, 1.78; 95% CI, 1.10-2.90; . P = .02), as demonstrated on multivariate analysis. In patients with high-risk disease, the recipient C/C genotype was associated with significantly worse overall survival rates than the recipient G/G genotype (HR, 1.60; 95% CI, 1.02-2.51; . P = .04), whereas this effect was absent in patients with standard-risk disease. In addition, the donor G/C genotype was associated with a lower incidence of relapse (HR, 0.58; 95% CI, 0.40-0.85), which did not influence survival. Our findings suggest that . PTPN22 genotyping could be useful in predicting prognoses and creating therapeutic strategies for improving the final outcomes of allogeneic BMT.

Original languageEnglish
Pages (from-to)240-246
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number2
DOIs
Publication statusPublished - 2013 Feb

Fingerprint

Graft vs Host Disease
Hematologic Neoplasms
Bone Marrow Transplantation
Genotype
Confidence Intervals
Incidence
Tissue Donors
Recurrence
Homologous Transplantation
Autoimmune Diseases
Japan
Multivariate Analysis
Survival Rate
Transplantation
Bone Marrow
T-Lymphocytes
Survival
Genes

Keywords

  • Lymphoid specific phosphatase
  • Promoter gene variant
  • Rs2488457
  • Single nucleotide variation
  • Unrelated donor

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Recipient PTPN22 -1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies. / Espinoza, J. Luis; Takami, Akiyoshi; Onizuka, Makoto; Morishima, Yasuo; Fukuda, Takahiro; Kodera, Yoshihisa; Akiyama, Hideki; Miyamura, Koichi; Mori, Takehiko; Nakao, Shinji.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 2, 02.2013, p. 240-246.

Research output: Contribution to journalArticle

Espinoza, J. Luis ; Takami, Akiyoshi ; Onizuka, Makoto ; Morishima, Yasuo ; Fukuda, Takahiro ; Kodera, Yoshihisa ; Akiyama, Hideki ; Miyamura, Koichi ; Mori, Takehiko ; Nakao, Shinji. / Recipient PTPN22 -1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 2. pp. 240-246.
@article{c60ced704aca469ea78e214fdd14d2e4,
title = "Recipient PTPN22 -1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies",
abstract = "PTPN22 is a critical negative regulator of T cell responses. Its promoter gene variant (rs2488457, -1123G>C) has been reported to be associated with autoimmune diseases. This study analyzed the impact of the . PTPN22 variant on transplantation outcomes in a cohort of 663 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. The recipient C/C genotype versus the recipient G/G genotype resulted in a lower incidence of grade II-IV acute graft-versus-host disease (hazard ratio [HR], 0.50; 95{\%} confidence interval [CI], 0.29-0.85; . P = .01), as well as a higher incidence of relapse (HR, 1.78; 95{\%} CI, 1.10-2.90; . P = .02), as demonstrated on multivariate analysis. In patients with high-risk disease, the recipient C/C genotype was associated with significantly worse overall survival rates than the recipient G/G genotype (HR, 1.60; 95{\%} CI, 1.02-2.51; . P = .04), whereas this effect was absent in patients with standard-risk disease. In addition, the donor G/C genotype was associated with a lower incidence of relapse (HR, 0.58; 95{\%} CI, 0.40-0.85), which did not influence survival. Our findings suggest that . PTPN22 genotyping could be useful in predicting prognoses and creating therapeutic strategies for improving the final outcomes of allogeneic BMT.",
keywords = "Lymphoid specific phosphatase, Promoter gene variant, Rs2488457, Single nucleotide variation, Unrelated donor",
author = "Espinoza, {J. Luis} and Akiyoshi Takami and Makoto Onizuka and Yasuo Morishima and Takahiro Fukuda and Yoshihisa Kodera and Hideki Akiyama and Koichi Miyamura and Takehiko Mori and Shinji Nakao",
year = "2013",
month = "2",
doi = "10.1016/j.bbmt.2012.09.014",
language = "English",
volume = "19",
pages = "240--246",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Recipient PTPN22 -1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies

AU - Espinoza, J. Luis

AU - Takami, Akiyoshi

AU - Onizuka, Makoto

AU - Morishima, Yasuo

AU - Fukuda, Takahiro

AU - Kodera, Yoshihisa

AU - Akiyama, Hideki

AU - Miyamura, Koichi

AU - Mori, Takehiko

AU - Nakao, Shinji

PY - 2013/2

Y1 - 2013/2

N2 - PTPN22 is a critical negative regulator of T cell responses. Its promoter gene variant (rs2488457, -1123G>C) has been reported to be associated with autoimmune diseases. This study analyzed the impact of the . PTPN22 variant on transplantation outcomes in a cohort of 663 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. The recipient C/C genotype versus the recipient G/G genotype resulted in a lower incidence of grade II-IV acute graft-versus-host disease (hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.29-0.85; . P = .01), as well as a higher incidence of relapse (HR, 1.78; 95% CI, 1.10-2.90; . P = .02), as demonstrated on multivariate analysis. In patients with high-risk disease, the recipient C/C genotype was associated with significantly worse overall survival rates than the recipient G/G genotype (HR, 1.60; 95% CI, 1.02-2.51; . P = .04), whereas this effect was absent in patients with standard-risk disease. In addition, the donor G/C genotype was associated with a lower incidence of relapse (HR, 0.58; 95% CI, 0.40-0.85), which did not influence survival. Our findings suggest that . PTPN22 genotyping could be useful in predicting prognoses and creating therapeutic strategies for improving the final outcomes of allogeneic BMT.

AB - PTPN22 is a critical negative regulator of T cell responses. Its promoter gene variant (rs2488457, -1123G>C) has been reported to be associated with autoimmune diseases. This study analyzed the impact of the . PTPN22 variant on transplantation outcomes in a cohort of 663 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. The recipient C/C genotype versus the recipient G/G genotype resulted in a lower incidence of grade II-IV acute graft-versus-host disease (hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.29-0.85; . P = .01), as well as a higher incidence of relapse (HR, 1.78; 95% CI, 1.10-2.90; . P = .02), as demonstrated on multivariate analysis. In patients with high-risk disease, the recipient C/C genotype was associated with significantly worse overall survival rates than the recipient G/G genotype (HR, 1.60; 95% CI, 1.02-2.51; . P = .04), whereas this effect was absent in patients with standard-risk disease. In addition, the donor G/C genotype was associated with a lower incidence of relapse (HR, 0.58; 95% CI, 0.40-0.85), which did not influence survival. Our findings suggest that . PTPN22 genotyping could be useful in predicting prognoses and creating therapeutic strategies for improving the final outcomes of allogeneic BMT.

KW - Lymphoid specific phosphatase

KW - Promoter gene variant

KW - Rs2488457

KW - Single nucleotide variation

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=84872523504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872523504&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.09.014

DO - 10.1016/j.bbmt.2012.09.014

M3 - Article

VL - 19

SP - 240

EP - 246

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -